Calcitonin is a 32-residue hormone with a long clinical history, and it illustrates how a peptide’s fortunes can change as better alternatives and better evidence arrive.
Key Takeaways
- Calcitonin is produced by thyroid parafollicular cells and lowers serum calcium by inhibiting osteoclast activity.
- Calcitonin aggregates readily in solution, which complicates both formulation and assay behaviour.
- The calcitonin story shows how potency in one species, wide historical use, and eventual evidence-based restriction can all apply to the same molecule.
Structure and source
Calcitonin is produced by thyroid parafollicular cells and lowers serum calcium by inhibiting osteoclast activity. Salmon calcitonin is more potent than the human form and has been widely used pharmaceutically, which is an unusual cross-species situation in peptide medicine.
Required structural features
The N-terminal disulfide bridge and the C-terminal proline amide are both required for activity. Removing either substantially reduces potency, making calcitonin another peptide whose function depends on post-translational features rather than on sequence alone.
For related mechanism work, see amylin pramlintide.
Aggregation in formulation
Calcitonin aggregates readily in solution, which complicates both formulation and assay behaviour. This property has made it a model compound for studying peptide aggregation and its control.
Clinical reassessment
The therapeutic role has narrowed considerably following reviews of efficacy and of possible long-term risk in some indications. Several markets have restricted or withdrawn certain products, which is a useful reminder that long-established peptide drugs are not exempt from re-evaluation.
Lessons
The calcitonin story shows how potency in one species, wide historical use, and eventual evidence-based restriction can all apply to the same molecule. Evidence standards evolve, and established products are reassessed against them.
Experimental Conditions and Practical Setup
Calcitonin assays must account for adsorption and for aggregation, both of which reduce the effective concentration. Because salmon calcitonin is substantially more potent than the human peptide in most assays, the species of the standard is stated, and potency is expressed against an international standard rather than by mass.
Calcitonin handling requirements
| Requirement | Reason | Consequence if ignored |
|---|---|---|
| Preserve the N-terminal disulfide | Required for receptor activation | Loss of activity |
| Retain the C-terminal proline amide | Required for potency | Much reduced potency |
| Use low-binding consumables | Peptide adsorbs to surfaces | Underdosing at low concentration |
| Control aggregation | Aggregates are inactive and immunogenic | Variable dose and immune risk |
Practical Notes for the Bench
- Preserve the N-terminal disulfide and C-terminal amide for activity.
- Expect aggregation behaviour in solution and plan formulation accordingly.
- Check current regulatory status before citing historical indications.
Frequently Asked Questions
Why is salmon calcitonin used?
It is substantially more potent than the human peptide, which is unusual but well established in clinical practice.
Which structural features are essential?
The N-terminal disulfide bridge and the C-terminal proline amide, both of which are required for full activity.
Is it still widely used?
The therapeutic role has narrowed after reviews of efficacy and risk, and availability varies by market.
Why was the clinical role reassessed?
Following reviews of efficacy and of possible long-term risk in some indications, several markets restricted or withdrew certain products. Long-established drugs are not exempt from re-evaluation.
Related Reading
- amylin pramlintide
- insulin analogue design
- PTH analogues bone research
- cell-penetrating peptides
- reproducible peptide experiments
References & Further Reading
- Neumüller J et al. Calcitonin in the Treatment of Phantom Limb Pain: A Systematic Review. CNS Drugs. 2023. PubMed 37261670
- Reginster JY et al. [Calcitonin]. Rev Med Liege. 1996. PubMed 8701121
- López de Novales E et al. [Calcitonin]. Rev Clin Esp. 1969. PubMed 4930178
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- Peptide research collection at Nature
All material on this page is intended for laboratory research and educational reference only. It is not medical advice, and it does not describe any approved diagnostic or therapeutic use.
Reviewed by Priya Raghunathan, MSc, Formulation & Stability Science.